Skip to main content

Table 1 Baseline characteristics of the patient population

From: Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer

Characteristic Stratum 1
(n = 16)
Stratum 2
(n = 8)
Stratum 3
(n = 2)
Overall
(n = 26)
Gender, n (%)
 Male 5 (31.3) 7 (87.5) 1 (50.0) 13 (50.0)
 Female 11 (68.8) 1 (12.5) 1 (50.0) 13 (50.0)
Age, years
 Median (range) 61.0 (40–74) 70.0 (58–83) 66.0 (59–73) 63.0 (40–83)
ECOG, n (%)
 0 5 (31.3) 0 2 (100.0) 7 (26.9)
 1 11 (68.8) 8 (100.0) 0 19 (73.1)
NSCLC duration at baseline, days
 Median (range) 131.0 (99–482) 117.0 (92–762) 167.0 (141–193) 123.5 (92–762)
Previous first-line chemotherapy
 Yes, n (%) 16 (100.0) 8 (100.0) 0 24 (92.3)
 No, n (%) 0 0 2 (100.0) 2 (7.7)
 Treatment response,a n (%)
  CR 0 0 0
  PR 9 (56.3) 3 (37.5) 12 (46.2)
  SD 7 (43.8) 5 (62.5) 12 (46.2)
  PD 0 0 0
  NE 0 0 0
Previous EGFR-TKI therapy
 Yes, n (%) 0 0 2 (100.0) 2 (7.7)
 No, n (%) 16 (100.0) 8 (100.0) 0 24 (92.3)
 Treatment response, n (%) 2 (100.0)b 2 (7.7)
  1. Abbreviations: CR complete response, ECOG Eastern Cooperative Oncology Group, EGFR-TKI epidermal growth factor receptor tyrosine kinase inhibitor, NE not evaluable, NSCLC non-small cell lung cancer, PR partial response, SD stable disease
  2. aWith respect to previous first-line chemotherapy for NSCLC (strata 1 and 2)
  3. bBoth patients had partial response